Ustekinumab
- Generic Name
- Ustekinumab
- Brand Names
- Stelara, Pyzchiva, Uzpruvo, Wezenla, Steqeyma, Otulfi, Fymskina, Eksunbi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 815610-63-0
- Unique Ingredient Identifier
- FU77B4U5Z0
- Background
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMAR...
- Indication
Ustekinumab is indicated for the management of moderate to severe plaque psoriasis in patients 6 years of age and older who are candidates for phototherapy or systemic therapy. In adult patients, it is also indicated for the management of active psoriatic arthritis (PsA) alone or in combination with methotrexate, moderately to severely active Crohn’s disease...
- Associated Conditions
- Severe Plaque psoriasis, Ulcerative Colitis, Active Severe, Active Psoriatic arthritis, Moderate Plaque psoriasis, Moderate Ulcerative colitis, Moderate, active Crohn´s Disease, Severe, active Crohn´s Disease
- Associated Therapies
- -
A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 563
- Registration Number
- NCT04607980
- Locations
- 🇨🇦
Toronto Research Centre - Dermatology, Toronto, Ontario, Canada
🇺🇸First OC Dermatology, Fountain Valley, California, United States
🇨🇦DermEdge Research Inc., Mississauga, Ontario, Canada
An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 13
- Registration Number
- NCT04549792
- Locations
- 🇺🇸
Northwestern University/Lurie Children's Hospital, Chicago, Illinois, United States
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 527
- Registration Number
- NCT04524611
- Locations
- 🇪🇸
Hospital Universitario Virgen Macarena /ID# 223315, Sevilla, Spain
🇪🇸Hospital Clinico Universitario de Valencia /ID# 223321, Valencia, Spain
🇨🇦Axler, Toronto, ON. Canada /ID# 223740, Toronto, Ontario, Canada
USTekinumab in Fistulising Perianal Crohn's Disease (USTAP)
- First Posted Date
- 2020-08-03
- Last Posted Date
- 2024-07-22
- Target Recruit Count
- 33
- Registration Number
- NCT04496063
- Locations
- 🇫🇷
APHP- Hopital Beaujon, Clichy, France
🇫🇷Chu Amiens, Amiens, France
🇫🇷CHU Nancy - Hôpital de Brabois, Vandœuvre-lès-Nancy, France
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT04435600
- Locations
- 🇩🇪
Universitaetsklinikum Carl Gustav Carus Dresden /ID# 228881, Dresden, Sachsen, Germany
🇯🇵Duplicate_Teikyo University Hospital /ID# 255188, Itabashi-ku, Tokyo, Japan
🇬🇧Duplicate_Royal Devon University Healthcare NHS Foundation Trust /ID# 228078, Exeter, Devon, United Kingdom
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 1056
- Registration Number
- NCT04372108
- Locations
- 🇺🇸
NMCP, Portsmouth, Virginia, United States
Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 12
- Registration Number
- NCT04305327
- Locations
- 🇪🇸
LEO Pharma Investigational Site, Valencia, Spain
🇩🇪LEO Pharm Investigational Site, Mainz, Germany
Loss of RESponse to Ustekinumab Treated by Dose Escalation
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2024-09-30
- Target Recruit Count
- 108
- Registration Number
- NCT04245215
- Locations
- 🇧🇪
Ingrid Arijs, Zaventem, Belgium
Efficacy and Safety of Ustekinumab in Bullous Pemphigoid
- First Posted Date
- 2019-10-07
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- CHU de Reims
- Target Recruit Count
- 18
- Registration Number
- NCT04117932
- Locations
- 🇫🇷
Damien JOLLY, Reims, France
Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 12
- Registration Number
- NCT04093531
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.